Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes

Pharmacogenomics Journal

Volumn 15, Issue 5, 2015, Pages 443-451

  Altar, C A ^a   Carhart, J M ^a   Allen, J D ^a   Hall Flavin, D K ^b   Dechairo, B M ^a   Winner, J G ^a  

^a Assurex Health   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DESIPRAMINE; DESVENLAFAXINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; SELEGILINE; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; SLC6A4 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL VALIDITY; CONTROLLED STUDY; CYP1A2 GENE; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; DEPRESSION; DISABILITY; DRUG RESPONSE; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HTR2A GENE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PHARMACOGENOMICS; PHENOTYPE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SLC6A4 GENE; VALIDITY; FEMALE; GENETICS; INBORN ERROR OF METABOLISM; MALE; PATHOLOGY; PHARMACOGENETICS; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 CYP2D6; DEPRESSION; FEMALE; HUMANS; MALE; METABOLISM, INBORN ERRORS; PHARMACOGENETICS; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TREATMENT OUTCOME;

EID: 84942198985     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2014.85     Document Type: Article

References (31)

1. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 2009; 48: 761-804.
2. Mrazek DA. Psychiatric Pharmacogenomics. Oxford University Press: New York, NY, 2010.
3. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103-141.
4. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-473.
5. Mrazek DA, Biernacka JM, O'Kane DJ, Black JL, Cunningham JM, Drews MS et al. CYP2C19 variation and citalopramresponse. Pharmacogenet Genomics 2011; 21: 1-9.
6. Altar CA, Hornberger J, Shewade A, Cruz V, Garrison J, Mrazek D. Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. Int Rev Psychiatry 2013; 25: 509-533.
7. Conrado DJ, Rogers HL, Zineh I, Pacanowski A. Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels. Pharmacogenomics 2013; 14: 215-223.
8. Citalopram (FDA): Package insert. http://www.accessdata.fda.gov/drugsatfda--docs/label/2009/020822s037,021046s015lbl.pdf.
9. Jürgens G, Jacobsen CB, Rasmussen HB, Werge T, Nordentoft M, Andersen SE. Utility and adoption of CYP2D6 and CYP2C19 genotyping and its translation into psychiatric clinical practice. Acta Psychiatr Scand 2012; 125: 228-237.
10. Recommendations from the EGAPP working group testing for cytrochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med 2007; 9: 819-825.
11. Dalén P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63: 444-452.
12. McAlpine DE, Biernacka JM, Mrazek DA, O'Kane DJ, Stevens SR, Langman LJ et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit 2011; 33: 14-20.
13. Jornil J, Nielsen TS, Rosendal I, Ahlner J, Zackrisson AL, Boel LWT et al. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic stimulation in a fatal drug poisoning case involving venlafaxine. Forensic Sci Int 2013; 226: e26-e31.
14. Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Procter B, Snyder KA et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics 2013; 23: 535-548.
15. Hall-Flavin DK, Winner JG, Allen JD, Jordan JJ, Nesheim RS, Snyder KA et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry 2012; 2: e172.
16. Winner JG, Carhart JM, Altar CA, Allen JD, Dechairo B. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med 2013; 16: 219-227.
17. Winner J, Allen J, Altar CA, Mihajlovic A. Genotype predicts health resource utilization of outpatients with anxiety and depression in a staff model health maintenance organization. Transl Psychiatry 2013; 3: e300.
18. Licinio J, Wong ML. Pharmacogenomics of antidepressant treatment effects. Dialogues Clin Neurosci 2011; 13: 63-71.
19. Herbild L, Andersen SE, Werge T, Rasmussen HB, Jurgens G. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?. Basic Clin Pharmacol Toxicol 2013; 11: 266-272.
20. Rush AJ, Bernstein IH, Trivedi MH, Carmody TJ, Wisniewski S, Mundt JC et al. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry 2006; 59: 493-501.
21. Ballinger GA. Using generalized estimating equations for longitudinal data analysis. Organ Res Methods 2004; 7: 127-150.
22. Ma Y, Mazumdar M, Memtsoudis SG. Beyond repeated-measures analysis of variance: advanced statistical methods for the analysis of longitudinal data in anesthesia research. Reg Anesth Pain Med 2012; 37: 99-105.
23. Zhang D, Lin X Variance component testing in generalized linear mixed models for longitudinal/clustered data and other related topics. Unpublished thesis. Accessed on 5 August 2013; www4.stat.ncsu.edu/~ dzhang2/st755/vartest.pdf.
24. Holm S. A simple sequentially rejective multiple test procedure. Scan J Statis 1979; 6: 65-70.
25. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 8: 326-331.
26. Lohoff FW, Narasimhan S, Rickels K. Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J 2012; 13: 464-469.
27. Villagra D, Goethe JW, Schwartz HI, Szarek B, Kocherla M, Gorowski K et al. Novel drug metabolism indices for pharmacogenetic functional status based on combinatorial genotyping of CYP2C9, CYP2C19 and CYP2D6 genes. Biomark Med 2011; 5: 427-438.
28. DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebocontrolled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007; 68: 677-688.
29. Stahl SM. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 2000; 48: 894-901.
30. Birnbaum HG, Kessler RC, Kelley D, Ben-Hammadi R, Joish VN, Greenberg PE. Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Depress Anxiety 2010; 27: 78-89.
31. Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. Psychiatric Serv 2014; 65: 977-987.